☆ 4.5 Article

Diagnosis and management of neuroendocrine tumours

CLINICAL MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Endocrinology & Metabolism

Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease Task Force)

Johannes Hofland et al.

Summary: The ENETS Expert Consensus document provides a standardized template for echocardiography in patients with NET and carcinoid syndrome, aiming to promote homogeneous evaluation of CHD and enable accurate assessment and comparison of study results.

JOURNAL OF NEUROENDOCRINOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms

Guido Rindi et al.

Summary: In this review, the changes and features of neuroendocrine neoplasms (NENs) in the 2022 WHO Classification of Endocrine and Neuroendocrine Tumors are detailed. The consolidation of nomenclature distinguishing different neoplasms and the importance of Ki67 as a tool for classification and grading are emphasized. The clinical relevance of proper classification and the tools available to pathologists for accurate classification are explained. The article also discusses the differential diagnoses and theranostic biomarkers for NENs, as well as the role of pathologists in identifying precursor lesions and applying molecular immunohistochemistry.

ENDOCRINE PATHOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease

Simona Grozinsky-Glasberg et al.

JOURNAL OF NEUROENDOCRINOLOGY (2022)

Add to Collection

Article Health Care Sciences & Services

Incidence and survival of neuroendocrine neoplasia in England 1995-2018: A retrospective, population- based study

Benjamin E. White et al.

Summary: The incidence of neuroendocrine neoplasias (NEN) is increasing in England, but survival rates are also improving over time. The relatively high survival rate compared to other cancers poses challenges for long-term outcomes and funding for care.

LANCET REGIONAL HEALTH-EUROPE (2022)

Add to Collection

Article Endocrinology & Metabolism

The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours

Daniel J. Cuthbertson et al.

Summary: This study evaluated the role of (68)Gallium (Ga-68)-DOTA PET/CT in managing patients with panNETs, showing that the imaging findings provided additional information in 54% of patients and influenced management in 39% of cases. The PET/CT scan more accurately stages and guides treatment in patients with sporadic/familial panNETs.

FRONTIERS IN ENDOCRINOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Surgery and Perioperative Management in Small Intestinal Neuroendocrine Tumors

Sophie Deguelte et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Oncology

Delays and routes to diagnosis of neuroendocrine tumours

Ron Basuroy et al.

BMC CANCER (2018)

Add to Collection

Review Cardiac & Cardiovascular Systems

Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors An Expert Statement

Joseph Davar et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)

Add to Collection

Article Endocrinology & Metabolism

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers

Kjell Oberg et al.

NEUROENDOCRINOLOGY (2017)

Add to Collection

Article Endocrinology & Metabolism

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging

Anders Sundin et al.

NEUROENDOCRINOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

J. Strosberg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

Arvind Dasari et al.

JAMA ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

James C. Yao et al.

LANCET (2016)

Add to Collection

Article Medicine, General & Internal

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

Martyn E. Caplin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Multidisciplinary Sciences

The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid Heart Disease: A Cross-Sectional Study

Rebecca Dobson et al.

PLOS ONE (2013)

Add to Collection

Article Medicine, General & Internal

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.

Eric Raymond et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Medicine, General & Internal

Everolimus for Advanced Pancreatic Neuroendocrine Tumors.

James C. Yao et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Oncology

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Anja Rinke et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Review Oncology

One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

James C. Yao et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.